NCT06387836

Brief Summary

Postoperative cognitive dysfunction (POCD) is a common complication after surgery that is associated with more adverse events and death. The goal of this randomized, controlled clinical study is to learn about the impact of different inhalation anesthetics may have on the elderly in terms of POCD and diagnosis performance of long intergenic non-coding RNA(LINC01844) level in blood of older people for POCD. The main question it aims to answer is: Dose the desflurane have less influence on the elderly's cognitive function in comparison with isoflurane?Does the relative level of LINC01844 in blood help diagnose POCD of older people after surgery? Participants undergoing elective lumbar decompression and fusion will finish neuropsychological evaluations one day before and 1st, 3rd and 5th day after surgery. At the same timepoint, the relative level of LINC01844 in blood will also be tested.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
85

participants targeted

Target at P50-P75 for not_applicable

Timeline
Completed

Started Apr 2024

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

April 23, 2024

Completed
Same day until next milestone

Study Start

First participant enrolled

April 23, 2024

Completed
6 days until next milestone

First Posted

Study publicly available on registry

April 29, 2024

Completed
1.1 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

May 31, 2025

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

May 31, 2025

Completed
Last Updated

June 27, 2025

Status Verified

June 1, 2025

Enrollment Period

1.1 years

First QC Date

April 23, 2024

Last Update Submit

June 24, 2025

Conditions

Keywords

postoperative cognitive dysfunctionlong intergenic non-coding RNAprediction biomarker

Outcome Measures

Primary Outcomes (1)

  • incidence of POCD

    The incidence of POCD is defined as the proportion of people who is diagnosed POCD at least once of the three times(on postoperative day 1, day 3 and day 5) in this group. POCD is diagnosed using the Z-score method. Patients were tested with a battery of 7 neurocognitive tests, and POCD was considered when the Z-score \> 1.961in two or more tests .

    From date of randomization until the date of telephone follow-up completed , assessed up to 2 months.

Secondary Outcomes (3)

  • serum reactive protein-C

    From date of randomization until the date of discharge , assessed up to 10 days.

  • serum interleukin-6

    From date of randomization until the date of discharge , assessed up to 10 days.

  • relative level of LINC01844

    From date of randomization until the date of discharge , assessed up to 10 days.

Study Arms (2)

Iso anesthesia

ACTIVE COMPARATOR

Patients in this group are under anesthesia with isoflurane.

Drug: Isoflurane 0.8 MAC

Des anesthesia

ACTIVE COMPARATOR

Patients in this group are under anesthesia with desflurane.

Drug: Desflurane 0.8MAC

Interventions

Patients in this group will be anesthetized using isoflurane with the depth of 0.8\~1.0MAC during the operation.

Iso anesthesia

Patients in this group will be anesthetized using desflurane with the depth of 0.8\~1.0MAC during the operation.

Des anesthesia

Eligibility Criteria

Age65 Years - 85 Years
Sexall
Healthy VolunteersNo
Age GroupsOlder Adult (65+)

You may qualify if:

  • Patients scheduled to perform elective lumbar decompression and interbody fusion under general anesthesia;
  • years old;
  • American Society of Anesthesiologists (ASA) physical status I-III level;
  • Body mass index (BMI) between 20 Kg/m2 and 28 Kg/m2;
  • From whom written informed consent is obtainable either from the patient or from a legal representative;

You may not qualify if:

  • Patents with cognitive dysfunction preoperatively;
  • Patents with verbal, visual and auditory defects;
  • Patients with history of alcohol and/or drug abuse, or history of neurological and psychotic disorders;
  • Patients with history of hospital admission and therapy within 30 days.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Zhongshan Hospital Fudan University

Shanghai, Shanghai Municipality, 200032, China

Location

Related Publications (18)

  • Pandin P, Estruc I, Van Hecke D, Truong HN, Marullo L, Hublet S, Van Obbergh L. Brain Aging and Anesthesia. J Cardiothorac Vasc Anesth. 2019 Aug;33 Suppl 1:S58-S66. doi: 10.1053/j.jvca.2019.03.042.

    PMID: 31279354BACKGROUND
  • Cortese GP, Burger C. Neuroinflammatory challenges compromise neuronal function in the aging brain: Postoperative cognitive delirium and Alzheimer's disease. Behav Brain Res. 2017 Mar 30;322(Pt B):269-279. doi: 10.1016/j.bbr.2016.08.027. Epub 2016 Aug 17.

    PMID: 27544872BACKGROUND
  • Mashour GA, Woodrum DT, Avidan MS. Neurological complications of surgery and anaesthesia. Br J Anaesth. 2015 Feb;114(2):194-203. doi: 10.1093/bja/aeu296. Epub 2014 Sep 8.

    PMID: 25204699BACKGROUND
  • Iqbal F, Thompson AJ, Riaz S, Pehar M, Rice T, Syed NI. Anesthetics: from modes of action to unconsciousness and neurotoxicity. J Neurophysiol. 2019 Aug 1;122(2):760-787. doi: 10.1152/jn.00210.2019. Epub 2019 Jun 26.

    PMID: 31242059BACKGROUND
  • Gitman M, Fettiplace MR, Weinberg GL, Neal JM, Barrington MJ. Local Anesthetic Systemic Toxicity: A Narrative Literature Review and Clinical Update on Prevention, Diagnosis, and Management. Plast Reconstr Surg. 2019 Sep;144(3):783-795. doi: 10.1097/PRS.0000000000005989.

    PMID: 31461049BACKGROUND
  • Carr ZJ, Cios TJ, Potter KF, Swick JT. Does Dexmedetomidine Ameliorate Postoperative Cognitive Dysfunction? A Brief Review of the Recent Literature. Curr Neurol Neurosci Rep. 2018 Aug 6;18(10):64. doi: 10.1007/s11910-018-0873-z.

    PMID: 30083844BACKGROUND
  • Zhang B, Tian M, Zhen Y, Yue Y, Sherman J, Zheng H, Li S, Tanzi RE, Marcantonio ER, Xie Z. The effects of isoflurane and desflurane on cognitive function in humans. Anesth Analg. 2012 Feb;114(2):410-5. doi: 10.1213/ANE.0b013e31823b2602. Epub 2011 Nov 10.

    PMID: 22075020BACKGROUND
  • Schallner N, Ulbrich F, Engelstaedter H, Biermann J, Auwaerter V, Loop T, Goebel U. Isoflurane but not sevoflurane or desflurane aggravates injury to neurons in vitro and in vivo via p75NTR-NF-kB activation. Anesth Analg. 2014 Dec;119(6):1429-41. doi: 10.1213/ANE.0000000000000488.

    PMID: 25329094BACKGROUND
  • Jiang J, Jiang H. Effect of the inhaled anesthetics isoflurane, sevoflurane and desflurane on the neuropathogenesis of Alzheimer's disease (review). Mol Med Rep. 2015 Jul;12(1):3-12. doi: 10.3892/mmr.2015.3424. Epub 2015 Mar 4.

    PMID: 25738734BACKGROUND
  • Miao H, Dong Y, Zhang Y, Zheng H, Shen Y, Crosby G, Culley DJ, Marcantonio ER, Xie Z. Anesthetic Isoflurane or Desflurane Plus Surgery Differently Affects Cognitive Function in Alzheimer's Disease Transgenic Mice. Mol Neurobiol. 2018 Jul;55(7):5623-5638. doi: 10.1007/s12035-017-0787-9. Epub 2017 Oct 6.

    PMID: 28986748BACKGROUND
  • He J, Huang B, Zhang K, Liu M, Xu T. Long non-coding RNA in cervical cancer: From biology to therapeutic opportunity. Biomed Pharmacother. 2020 Jul;127:110209. doi: 10.1016/j.biopha.2020.110209. Epub 2020 May 20.

    PMID: 32559848BACKGROUND
  • Lu G, Zhao W, Rao D, Zhang S, Zhou M, Xu S. Knockdown of long noncoding RNA WNT5A-AS restores the fate of neural stem cells exposed to sevoflurane via inhibiting WNT5A/Ryk-ROS signaling. Biomed Pharmacother. 2019 Oct;118:109334. doi: 10.1016/j.biopha.2019.109334. Epub 2019 Aug 16.

    PMID: 31545269BACKGROUND
  • Zhao Y, Ai Y. Overexpression of lncRNA Gm15621 alleviates apoptosis and inflammation response resulting from sevoflurane treatment through inhibiting miR-133a/Sox4. J Cell Physiol. 2020 Feb;235(2):957-965. doi: 10.1002/jcp.29011. Epub 2019 Jul 2.

    PMID: 31264218BACKGROUND
  • Niu X, Pu S, Ling C, Xu J, Wang J, Sun S, Yao Y, Zhang Z. lncRNA Oip5-as1 attenuates myocardial ischaemia/reperfusion injury by sponging miR-29a to activate the SIRT1/AMPK/PGC1alpha pathway. Cell Prolif. 2020 Jun;53(6):e12818. doi: 10.1111/cpr.12818. Epub 2020 May 28.

    PMID: 32468629BACKGROUND
  • Tu Y, Zhu M, Wang Z, Wang K, Chen L, Liu W, Shi Q, Zhao Q, Sun Y, Wang X, Song E, Liu X. Melatonin inhibits Muller cell activation and pro-inflammatory cytokine production via upregulating the MEG3/miR-204/Sirt1 axis in experimental diabetic retinopathy. J Cell Physiol. 2020 Nov;235(11):8724-8735. doi: 10.1002/jcp.29716. Epub 2020 Apr 23.

    PMID: 32324260BACKGROUND
  • Wang S, Han X, Mao Z, Xin Y, Maharjan S, Zhang B. MALAT1 lncRNA Induces Autophagy and Protects Brain Microvascular Endothelial Cells Against Oxygen-Glucose Deprivation by Binding to miR-200c-3p and Upregulating SIRT1 Expression. Neuroscience. 2019 Jan 15;397:116-126. doi: 10.1016/j.neuroscience.2018.11.024. Epub 2018 Nov 26.

    PMID: 30496821BACKGROUND
  • Sun LY, Li XJ, Sun YM, Huang W, Fang K, Han C, Chen ZH, Luo XQ, Chen YQ, Wang WT. LncRNA ANRIL regulates AML development through modulating the glucose metabolism pathway of AdipoR1/AMPK/SIRT1. Mol Cancer. 2018 Aug 22;17(1):127. doi: 10.1186/s12943-018-0879-9.

    PMID: 30134922BACKGROUND
  • Jin D, Ma Y, Ji Y, Ge S. Impact of desflurane versus isoflurane on early cognitive function of the elderly undergoing lumbar surgery: a randomized clinical trial. BMC Anesthesiol. 2025 Dec 9;25(1):605. doi: 10.1186/s12871-025-03493-1.

MeSH Terms

Conditions

Postoperative Cognitive Complications

Condition Hierarchy (Ancestors)

Postoperative ComplicationsPathologic ProcessesPathological Conditions, Signs and SymptomsCognitive DysfunctionCognition DisordersNeurocognitive DisordersMental Disorders

Study Officials

  • Shengjin Ge, Ph.D.

    Fudan University

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
PARTICIPANT, OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

April 23, 2024

First Posted

April 29, 2024

Study Start

April 23, 2024

Primary Completion

May 31, 2025

Study Completion

May 31, 2025

Last Updated

June 27, 2025

Record last verified: 2025-06

Data Sharing

IPD Sharing
Will not share

There isn't an IPD plan yet. Full access to the final trial dataset will only be granted to selected investigators for publication issues.

Locations